Table 4.
Characteristics | n | Grade I–II | Conventional grade III | HGT | P-value |
---|---|---|---|---|---|
Gender | 0.15 | ||||
Male | 33 (45.2) | 21 (44.7) | 8 (66.7) | 4 (28.6) | |
Female | 40 (54.8) | 26 (55.3) | 4 (33.3) | 10 (71.4) | |
Age groups | 0.566 | ||||
≤50y | 37 (50.7) | 26 (55.3) | 5 (41.7) | 6 (42.9) | |
>50y | 36 (49.3) | 21 (44.7) | 7 (58.3) | 8 (57.1) | |
Primary sites | 0.641 | ||||
Major salivary | 17 (23.3) | 7 (14.9) | 4 (33.3) | 6 (42.9) | |
Nasal cavity and paranasal sinuses | 15 (20.5) | 10 (21.3) | 2 (16.7) | 3 (21.4) | |
lip and oral cavity | 15 (20.5) | 10 (21.3) | 2 (16.7) | 3 (21.4) | |
Trachea | 9 (12.3) | 7 (14.9) | 2 (16.7) | 0 (0) | |
Pharynx | 7 (9.6) | 6 (12.8) | 1 (8.3) | 0 (0) | |
External auditory canal | 5 (6.8) | 3 (6.4) | 1 (8.3) | 1 (7.1) | |
Larynx | 3 (4.1) | 3 (6.4) | 0 (0) | 0 (0) | |
Lacrimal gland | 2 (2.7) | 1 (2.1) | 0 (0) | 1 (7.1) | |
PNI | 0.169 | ||||
Negative | 12 (16.4) | 10 (21.3) | 2 (16.7) | 0 (0) | |
Positive | 61 (83.6) | 37 (78.7) | 10 (83.3) | 14 (100) | |
Margin status | 0.422 | ||||
≥1 mm | 11 (15.1) | 9 (19.1) | 1 (8.3) | 1 (7.1) | |
<1 mm | 62 (84.9) | 38 (80.9) | 11 (91.7) | 13 (92.9) | |
T stage | 0.127 | ||||
1–2 | 20 (27.4) | 14 (29.8) | 4 (33.3) | 2 (14.3) | |
3 | 34 (46.6) | 25 (53.2) | 4 (33.3) | 5 (35.7) | |
4 | 19 (26) | 8 (17) | 4 (33.3) | 7 (50) | |
LNM (n = 34) | 0.009 | ||||
Negative | 25 (73.5) | 20 (87) | 3 (75) | 2 (28.6) | |
Positive | 9 (26.5) | 3 (13) | 1 (25) | 5 (71.4) | |
Stage groups | 0.039 | ||||
I–II | 19 (26) | 14 (29.8) | 4 (33.3) | 1 (7.1) | |
III | 31 (42.5) | 23 (48.9) | 4 (33.3) | 4 (28.6) | |
IV | 23 (31.5) | 10 (21.3) | 4 (33.3) | 9 (64.3) | |
PORT (n = 68) | 0.664 | ||||
Yes | 39 (57.4) | 27 (61.4) | 6 (50) | 6 (50) | |
No | 29 (42.6) | 17 (38.6) | 6 (50) | 6 (50) |
HGT, high-grade transformation; PNI, perineural invasion; LNM, lymph node metastasis; PORT, postoperative radiotherapy.